全文获取类型
收费全文 | 372266篇 |
免费 | 15226篇 |
国内免费 | 5827篇 |
专业分类
耳鼻咽喉 | 4272篇 |
儿科学 | 9402篇 |
妇产科学 | 6085篇 |
基础医学 | 45239篇 |
口腔科学 | 6000篇 |
临床医学 | 33310篇 |
内科学 | 65098篇 |
皮肤病学 | 5843篇 |
神经病学 | 30576篇 |
特种医学 | 18513篇 |
外国民族医学 | 37篇 |
外科学 | 52270篇 |
综合类 | 13162篇 |
现状与发展 | 19篇 |
一般理论 | 38篇 |
预防医学 | 29412篇 |
眼科学 | 7658篇 |
药学 | 27661篇 |
60篇 | |
中国医学 | 5916篇 |
肿瘤学 | 32748篇 |
出版年
2024年 | 325篇 |
2023年 | 2128篇 |
2022年 | 5621篇 |
2021年 | 8349篇 |
2020年 | 5084篇 |
2019年 | 5693篇 |
2018年 | 27625篇 |
2017年 | 22183篇 |
2016年 | 24975篇 |
2015年 | 9660篇 |
2014年 | 11254篇 |
2013年 | 12148篇 |
2012年 | 23419篇 |
2011年 | 37055篇 |
2010年 | 28170篇 |
2009年 | 19305篇 |
2008年 | 30370篇 |
2007年 | 32110篇 |
2006年 | 10805篇 |
2005年 | 11795篇 |
2004年 | 11195篇 |
2003年 | 11282篇 |
2002年 | 8481篇 |
2001年 | 5112篇 |
2000年 | 4889篇 |
1999年 | 4029篇 |
1998年 | 2113篇 |
1997年 | 1834篇 |
1996年 | 1363篇 |
1995年 | 1242篇 |
1994年 | 1109篇 |
1993年 | 780篇 |
1992年 | 1434篇 |
1991年 | 1309篇 |
1990年 | 1219篇 |
1989年 | 1017篇 |
1988年 | 905篇 |
1987年 | 835篇 |
1986年 | 628篇 |
1985年 | 623篇 |
1984年 | 436篇 |
1983年 | 321篇 |
1982年 | 206篇 |
1981年 | 234篇 |
1980年 | 209篇 |
1979年 | 292篇 |
1978年 | 213篇 |
1976年 | 188篇 |
1974年 | 196篇 |
1973年 | 162篇 |
排序方式: 共有10000条查询结果,搜索用时 8 毫秒
101.
Seppo W. Langer 《Current oncology reports》2010,12(4):242-246
Extravasation of chemotherapy is a feared complication of anticancer therapy. The accidental leakage of cytostatic agents
into the perivascular tissues may have devastating short-term and long-term consequences for patients. In recent years, the
increased focus on chemotherapy extravasation has led to the development of international guidelines that have proven useful
tools in daily clinical practice. Moreover, the tissue destruction in one of the most dreaded types of extravasation (ie,
anthracycline extravasation) now can effectively be prevented with a specific antidote, dexrazoxane. 相似文献
102.
Carlos Ferrer Albiach Antonio Conde Moreno Marta Rodríguez Cordón Virginia Morillo Macías Ana Bouché Babiloni Inmaculada Beato Tortajada Ángel Sánchez Iglesias Alicia Francés Muñoz 《Clinical & translational oncology》2010,12(1):22-26
Hypoxia is related to poor prognosis because it is associated to chemo-and radioresistance. During recent years the evolution
of imaging methods like PET/CT and MRI has meant the appearance of new perspectives with direct implications in radiation
therapy. We discuss previous experiences in staging, planning and in the follow-up process with these techniques for measuring
tumour hypoxia. 相似文献
103.
Lidong Zhang James E Littlejohn Yu Cui Xiaobo Cao Chander Peddaboina W Roy Smythe 《Molecular cancer》2010,9(1):110
Background
Bortezomib, a proteasome-specific inhibitor, has emerged as a promising cancer therapeutic agent. However, development of resistance to bortezomib may pose a challenge to effective anticancer therapy. Therefore, characterization of cellular mechanisms involved in bortezomib resistance and development of effective strategies to overcome this resistance represent important steps in the advancement of bortezomib-mediated cancer therapy. 相似文献104.
Background
The fibromyalgia syndrome (FMS) is suggested to be a manifestation of depression or affective spectrum disorder. We measured the cognitive style of patients with FMS to assess personality styles in 44 patients with fibromyalgia syndrome (FMS) by comparing them with 43 patients with major depressive disorder (MDD) and 41 healthy controls (HC). 相似文献105.
106.
107.
108.
109.
试析陆懋修从阳明论治温病之特色 总被引:1,自引:0,他引:1
陆懋修(1818-1886),又名免研,字九芝,号江左下工,又号林屋山人,江苏元和(今江苏吴县)人,为清代后期著名的医学家。陆氏出身于官宦之家,儒医兼通,陆氏秉承家学,对先人的医学成就颇为敬重。他曾三十余年坚持潜心研究《内经》、《伤寒》等医学经典著作,终于贯通医理而成为一代名医。陆氏一生博览群书之余,著述不断, 相似文献
110.
Diseases like rotavirus afflict both upper- and lower-income countries, but most serious illnesses and deaths occur among the latter. It is a vital public health issue that vaccines for these types of global diseases can recover research and development (R&D) costs from high-priced markets quickly so that manufacturers can offer affordable prices to lower-income nations. Cost recovery depends on how high R&D costs are, and this study attempts to replace high, unverified estimates with lower, more verifiable estimates for two new vaccines, RotaTeq (Merck) and Rotarix (GlaxoSmithKline or GSK), based on detailed searches of public information and follow-up interviews with senior informants. We also offer a new perspective on “cost of capital” as a claim for recovery from public bodies. Our estimates suggest that companies can recover all fixed costs quickly from affluent markets and thus can offer these vaccines to lower-income countries at prices they can afford. Better vaccines are a shared project between companies and public health agencies; greater transparency and consistency in reporting of R&D costs is needed so that fair prices can be established. 相似文献